Multiparametric arrayed CRISPR screen in iPSC derived macrophages (pdf: 2.2mb)
Matteo Martufi (GlaxoSmithKline)

CRISPR/Cas9-based therapeutic strategies for β-hemoglobinopathies (pdf: 13.3mb)
Annarita Miccio (Institute of Genetic Diseases)

Engineering Cells for Increased Therapeutic Potency and Safety (pdf: 11.7mb)
Matthew Porteus (Stanford University)

Optical pooled screens in human cells (pdf: 4.9mb)
Avtar Singh (Broad Institute)

Cell and Gene Editing Therapy of Metabolic Liver Disease (pdf: 7.7mb)
Stephen Strom (Karolinska Institutet, Stockholm)

GABAA Receptor Subtype Selective Compounds – Where Are We Now? (pdf: 5.2MB)
Professor John Atack (Medicines Discovery Institute, Cardiff University)

CRYO-EM and X-RAY free electron laser enabled structure based drug discovery on challenging membrane protein targets (pdf: 4.9MB)
Michael Hennig (leadXpro AG)

Nurturing effective translation (pdf: 2.3MB)
Melanie Lee (LifeArc)

Mass Spectrometry – A Useful Addendum for Multimodal Imaging Pipelines? (pdf:28.4mb)
Martina Marchetti-Deschmann (Institute of Chemical Technologies and Analyics, TU Wien, 1060 Vienna, Austria)

Targeting Voltage-gated Calcium Channels In Disease: Modulation Of Cav3 Calcium Channels By The Cachd1 Protein (pdf: 11.8mb)
Gary Stephens (University of Reading)

Organoids: A Patient in the lab (pdf: 4MB)
Robert Vries (Hubrecht Organoid Technology)

Innovative cancer drug discovery – Progress, opportunities and future challenges (pdf: 7.3mb)
Professor Paul Workman (CRUK Cancer Therapeutics Unit The Institute of Cancer Research, London UK)

Advances in Phenotypic Screening: Accelerating the Discovery of New Chemical Entities and Drug Combinations toward in vivo proof-of-concept (pdf: 9.2mb)
Professor Neil Carragher (Edinburgh University)

Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That are Retained in Corresponding Malignant Cell Types (pdf: 7.2mb)
Muntasir Mamun Majumder (University of Helsinki)

Editing the genome of human iPSCs using CRISPR/Cas9:Disease modelling and beyond… (pdf: 4.4mb)
Andrew Bassett (Wellcome Sanger Institute)

Artificial Intelligence in Drug Design (pdf: 2.4mb)
Ola Engkvist (AstraZeneca)

How do we drive the evolution and implementation of novel in vitro techniques in partnership with in vivo, ex vivo and in silico siblings? (pdf: 6.7mb)
Mark Holbrook (Certara)

Bioelectronics – is the next novel therapy class an electronic implant? (pdf: 19.5mb)
Jason Witherington (Galvani Bioelectronics)

Genome Editing of Hematopoietic Stem Cells to Treat Genetic Diseases (pdf: 20.9mb)
Dr Matthew Porteus (Stanford University)

High efficiency genome editing using a novel mutant AsCas12a (pdf: 2.2mb)
Dr Mark Behlke (Integrated DNA Technologies)

Day 1

How the chemical design and synthesis of linkers used in antibody drug conjugates drives the success of ADC drug development (pdf: 3.3mb)
Mark Frigerio (Abzena)

Drug Discovery: Reductionism v Complexity (pdf: 2.4mb)
Steven Zimmer (MitoDys and EpiCombi Therapeutics)

Combination Chemotherapy to Combat Antimicrobial Resistance (pdf: 3.2mb)
Professor William Hope (University of Liverpool)

Biomicrofabrication of Cellular Interfaces and Models (pdf: 27.6mb)
Dr Cristina Bertulli (University of Cambridge)

Potential for delta opioid receptor agonists as analgesics in chronic pain therapy (pdf: 2mb)
David Kendall (PharmNovo AB/UK)

Day 2

Medicines Discovery Catapult: a new model for collaborative R&D (pdf: 2.8mb)
Graeme Wilkinson (Medicines Discovery Catapult)

Building BRIDGEs: An Academic-Industry exercise (pdf: 1.3mb)
Mark Slack (Evotec)

Smarter IDO inhibitor profiling using biophysical, biochemical and cellular target engagement approaches (pdf: 3.1mb)
Dr Scott Pollack (Sygnature Discovery)

Fluorescence assay technologies for hit discovery (pdf: 1.3mb)
Helena Lindmark (AstraZeneca)

From One to Ten – Building Single and Interconnected Microphysiological Systems (pdf: 5.4mb)
Dr David Hughes (CTO, CN Bio)

In vitro-in vivo extrapolation from organ on a chip systems (pdf: 3mb)
Iain Gardener (Certara)

The union of organs-on-chips and mass spectrometric multi-omics: a technological convergence that will advance drug discovery (pdf: 24mb)
John Wikswo (Vanderbilt University)

AI-Based Assessment of Cognitive Impairment in Neurodegenerative Diseases (pdf: 6.7mb)
Seyed Mahdi Khaligh Razavi (Cognetivity)

Modernising Pharma R&D. Why, What and How (pdf: 1mb)
Laura Williams (GlaxoSmithKline)

Some economic aspects of robotics and automation for the laboratory (pdf: 2.3mb)
Patrick Courtney (tec-connection)

What could be driving the Lab of the future and is the ‘Smart Lab’ really a thing? (pdf: 2mb)
Paul Kendall (FESTO)

Using the Medicinal Chemistry Toolkit app supporting good translational science in projects (pdf: 3.3mb)
Andy Davis AstraZeneca)

The convergence of artificial intelligence and chemistry for drug discovery (pdf: 1.5mb)
Clive Green (AstraZeneca)

The value of Binding Kinetics in Drug Action (pdf: 1.5mb)
David Swinney (iRND3)

Big Pharma – Can We Fix It? (pdf: 2.4mb)
Nessa Carey (Carey International Impact Training)

Optimizing Binding Kinetics in Medicinal Chemistry: facts or fantasy? (pdf: 5mb)
Gerhard Müller (Gotham Therapeutics)

Using human genetics to make new medicines (pdf: 3.5mb)
Maya Ghoussaini (Open targets, Wellcome Trust Sanger Institute)

PKTool; a software tool to help decision making in early drug discovery (pdf: 4.6mb)
Neil Benson (Certara QSP)

Physiologically-Based Pharmacokinetics (PBPK) to Bridge between
In Vitro Discovery and In Vivo Human Studies (pdf: 7.9mb)
Amin Rostami (University of Manchester)

Tooling up to tackle cell wall biosynthesis (pdf: 2.7mb)
Chris Dowson (University of Warwick)